The CE Mark gives Intrinsic approval to distribute the Barricaid throughout the EU and in other countries that recognize the CE Mark.
According to Intrinsic Therapeutics, the Barricaid offers a new surgical strategy by reconstructing the anulus and anchoring it to the vertebral body for a more secure solution.
Greg Lambrecht, president and CEO of Intrinsic Therapeutics, said: “This approval gives Intrinsic the opportunity to offer surgeons, patients, and payers the potential for a truly better outcome in the treatment of lumbar disc herniation, the most common degenerative condition of the spine.
“The Barricaid and its approval in the EU is the culmination of years of extensive preclinical and clinical development to address this fundamental, unmet need in spine surgery.”